Emerging mechanisms for secondary cardioprotective effects of statins

Cardiovascular Research

Volumn 52, Issue 1, 2001, Pages 5-7

  Miller, Steven J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CELL RECEPTOR; LOW DENSITY LIPOPROTEIN; LOX 1 RECEPTOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTICOAGULATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVITY; ENZYME REGULATION; HEART FUNCTION; HEART PROTECTION; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTITHROMBINS; CELL ADHESION; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LDL; RECEPTORS, OXIDIZED LDL; SCAVENGER RECEPTORS, CLASS E;

EID: 0034850905     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00418-7     Document Type: Editorial

References (28)

1. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
2. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum
3. A new hypocholesterolemic agent produced by a Monascus species
4. Mevinolin, a highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol-lowering agent
5. Lessons learned from statin trials
6. Assessing the results: Phase 1 hyperlipidemia outcomes in 27 health plans
7. What do the statin trials tell us?
8. Pleiotropic effects of statins
9. Fluvastatin: Effects beyond cholesterol lowering
10. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability
11. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation
12. Non-lipid-lowering effects of statins on atherosclerosis
13. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?
14. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species
15. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes
16. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism
17. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells
18. Long-term effects of pravastatin on plasma concentration of C-reactive protein
19. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
20. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
21. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients
22. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
23. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation
24. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
25. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
26. Statins as a newly recognized type of immunomodulator
27. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells
28. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells